AlphAIAlphAI — Financial news for AI agents
tradingview.com$FISK

Empire State Realty 3Q 2026: Revenue $193.05M, EPS $0.02 — 10-Q Summary

Empire State Realty reported 3Q 2026 revenue of $193.05M, down 2.4% YoY, and net income of $4.85M, down 61.5% YoY. Rental revenue rose 2.2%, but Observatory revenue fell 25.6% due to lower visitation. The company sold two properties for a total of $492.5M.

Original reporting
tradingview.com
Published Nov 9, 2026, 10:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 10:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Empire State Realty 3Q 2026: Revenue $193.05M, EPS $0.02 — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$FISKBearishLow
01

Why it matters

Earnings miss suggests short‑term downside pressure; however, asset sales could support longer‑term stability.

02

Market read

Primary earnings disclosure for a small‑cap REIT; modest trading relevance.

03

What to watch

Recent property sales may improve balance sheet liquidity despite earnings miss.

Relevance 5/10Novelty 5/10Timing: after-hours release

Background

Empire State Realty OP, L.P. filed its Q3 2026 10‑Q, reporting lower revenue and EPS versus the prior year.

Company-level read

Ticker impact

$FISKBearishMedium confidence
Context

10-Q filing shows Q3 revenue $193.05M and EPS $0.02, down YoY, indicating earnings miss.

Expected impact

likely downside as market prices in weaker revenue and EPS.

Evidence & confidence

Revenue and EPS both declined year‑over‑year; investors typically react negatively to such misses.

Market effects

Sector

Real estate REIT sector may see modest pressure if peers report similar trends.

Regional

Limited to US REIT investors.

Global

Low; impact confined to niche REIT space.

Counterpoint

What could challenge this read

If the decline is temporary and the portfolio sales provide cash, the stock could be a buying opportunity at lower levels.

Key entities

  • Company
    Empire State Realty OP, L.P.

    Real estate investment trust focused on office and retail properties.

Read at source← All news

Related articles

$DDOGHighAI 9/10

“Missing Forest-for-the-Trees”: Datadog Sinks 17% in a Week as Its Biggest AI Customer Cuts Back

Datadog (DDOG) stock fell 17% in a week after reporting 35% Q3 revenue growth to $1.2B but guiding Q4 revenue to $1.19-1.2B, roughly flat. The decline was driven by its largest AI customer reducing usage, though growth outside this customer is accelerating. Cloudflare (NET) reported strong Q3 results and a rising Q4 outlook, suggesting the slowdown may be isolated. Datadog trades at 60x forward earnings, below its usual multiple.

finance.yahoo.com
$NOVTHighAI 8/10

Novanta (NOVT) Q3 2026 Earnings Call Transcript

Novanta (NOVT) reported Q3 2026 revenue of $305M, up 23%, with organic growth of 10%. Adjusted EBITDA rose 38% to $80M, and adjusted EPS increased 21% to $1.05. The company acquired Riverpoint Medical, expanding its medical end markets to 53% of revenue. Customer bookings grew 29%, and backlog reached $543M. Operating cash flow tripled year-over-year to $156M. Novanta expects full-year 2027 gross margin expansion and strong earnings growth, driven by new products and acquisitions.

finance.yahoo.com
$AXONMed

Axon Sinks 27% in a Week to a New 52-Week Low. Is the Selling Overdone?

Axon shares dropped 27% in a week to a 52-week low after missing Q3 revenue estimates and lowering its 2026 outlook due to delayed federal Dedrone deployments. The company now expects $350M-$400M in free cash flow by 2026, down from $450M, and needs $450M in Q4 to meet targets. Competitors Motorola Solutions and Tyler Technologies reported strong demand. Analysts reduced 2027 EPS estimates to $9.55 from $10.51.

finance.yahoo.com
$INOHighAI 8/10

Inovio Q3 2026 slides: VOCERYQ approval amid wider loss

Inovio Pharmaceuticals reported a Q3 2026 net loss of $49.2M, wider than expected, despite FDA approval of VOCERYQ. Shares fell 3.97% to $1.45, then another 10.34% after hours. Operating expenses declined 7% YoY, but non-cash losses increased. Cash reserves total $48.4M, with a runway into late 2027. VOCERYQ targets recurrent respiratory papillomatosis, showing 50-100% surgery reduction in trials. The company plans a Q1 2027 launch and European filings by year-end.

investing.com